Kamada completes patient enrolment in Phase II/III study of rabies vaccine KamRAB

Israel-based Kamada has completed patient enrolment in its US Phase II/III clinical trial of KamRAB as a post-exposure prophylaxis (PEP) treatment for rabies.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news